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Key Points
• The presence of MetS
components in patients
with DVT is associated
with significantly higher
rates of VTE
recurrence.
An improved understanding of which patients are at higher risk of recurrent venous
thromboembolism (VTE) is important to designing interventions to reduce degraded quality
of life after VTE. Although metabolic syndrome (MetS), the clustering of hypertension,
hyperlipidemia, diabetes mellitus, and obesity has been associated with a hypofibrinolytic
state, data linking VTE recurrence with MetS remain limited. The purpose of this study was
tomeasure the prevalence ofMetS in patientswith deep vein thrombosis (DVT) across a large
population and determine its effect on VTE recurrence. This was a retrospective analysis of
a large statewide database from 2004 to 2017. We measured the frequency with which
patients with DVT carried a comorbid International Coding of Diseases diagnosis of MetS
components. Association of MetS with VTE recurrence was tested with a multiple logistic
regression model and VTE recurrence as the dependent variable. Risk of VTE recurrence
conferred by each MetS component was assessed by Kaplan-Meier curves with the log-rank
statistic. A total of 151 054 patients with DVT were included in this analysis. Recurrence of
VTE occurred in 17% overall and increased stepwise with each criterion for MetS. All 4
components of MetS had significant adjusted odds ratios (OR) for VTE recurrence, with
hyperlipidemia having the largest (OR, 1.8), representing the 4 largest ORs of all possible
explanatory variables. All 4 MetS variables were significant on Kaplan-Meier analysis for
recurrence of VTE. These data imply a role for appropriate therapies to reduce the effects
of MetS as a way to reduce risk of VTE recurrence.
Introduction
Venous thromboembolism (VTE), comprising both deep vein thrombosis (DVT) and pulmonary embolism
(PE), poses a significant burden to public health, with an annual incidence estimated to be between 1
and 2 per 1000 of the US population.1-3 Nearly two-thirds of these events represent patients presenting
with DVT.4 Recurrence of VTE remains a scourge to patients with DVT, with 1 study finding a continued
risk of recurrence of 11% in the first year after cessation of anticoagulation therapy, with a 5% risk in the
subsequent year.5 Further, between one-third and one-half of patients diagnosed with DVT will develop
postthrombotic syndrome, which is characterized by chronic, debilitating leg pain, edema, and skin
ulcerations, resulting from residual venous obstruction and valvular reflux, with the probability of
postthrombotic syndrome increasing with DVT recurrence.6,7
The prevalence of obesity continues to rise, doubling worldwide over the past 3 decades.8 Increasing
in parallel with obesity is the prevalence of metabolic syndrome (MetS), now estimated to afflict at
least 34% of the US population.9 MetS is generally defined as a clustering of the following clinical
criteria: abdominal obesity, impaired glucose metabolism, dyslipidemia, and hypertension.10 MetS is
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associated with a procoagulant and hypofibrinolytic state, with prior
work demonstrating prolonged clot lysis times in patients with MetS
compared with controls.11 Among other mechanisms, MetS is
associated with a dysregulated secretion of adipokines caused
by excess adipose tissue that may create a chronic low-grade
inflammatory state leading to endothelial dysfunction, vascular
remodeling, and thrombosis.12-14 Although prior studies have
suggested the components of MetS are associated with higher
risk of first VTE event, data linking MetS with VTE recurrence
remain less defined and conflicted in their conclusions.15-24 An
improved understanding of the causal effect of MetS on VTE and
its recurrencemay aid in clinical decision-making regarding appropriate
treatment and prompt initiation of adjuvant therapies aimed at
reducing risk factors for recurrence at the time of VTE diagnosis.
The purpose of this study was to measure the prevalence of MetS in
patients with DVT across a large study population and to determine
its effect on VTE recurrence and mortality.
Methods
Overall study design
This was a population-based analysis using deidentified patient
information from a large statewide database, the Indiana Network
for Patient Care, in collaboration with the Regenstrief Institute.
This database is the primary platform that enables the Indiana
Health Information Exchange, 1 of the largest health information
exchanges nationwide, with data collected from the combination
of these institutions representing .10 billion clinical elements in
total. Inclusion criteria for this retrospective study was any diagnosis
of DVT based on Sequel-based query of these databases for the
appropriate International Coding of Diseases (ICD) codes (ICD-9
[453.x] or ICD-10 [I82.x]) from 2004 to 2017.
The presence or absence of each of the components of MetS in
patients found to have a DVT diagnosis was determined based on
ICD coding for the following 4 conditions: hypertension (401-404.x,
I10-I13.x), hyperlipidemia (272.x, E78.x, E88.1), diabetes mellitus
(250.x0, 250.x2, E11.x), or obesity (278.x, E66.x). This ICD-based
diagnosis could have been coded at any time during the study
period from 2004 to 2017 and was not necessarily always at the
time of index DVT. We also collected additional data including
pertinent demographics (eg, sex, race, age), presence or absence
of specified comorbidities (atrial fibrillation [Afib], chronic obstruc-
tive pulmonary disease [COPD], congestive heart failure [CHF],
anxiety, depression, stroke, myocardial infarction [MI], chronic kidney
disease [CKD], multiple cancer diagnoses [esophageal, breast, lung,
liver, testicular, pancreatic, prostate, ovarian, melanoma]), medication
history, smoking history, number of subsequent return visits to the
emergency department (ED) within 2 years post-DVT diagnosis,
history of recurrent VTE event, and current vital status. Recurrent
VTE was defined as any subsequent ICD-based diagnosis of DVT
or PE occurring after the index DVT.
Statistical analysis
Statistical analyses were performed using SAS software, version 9.4
(Cary, NC). We measured the prevalence of each MetS component
in patients with DVT, as well as the summative frequency with which
patients carried 0, 1, 2, 3, or 4 of these components. We constructed
Kaplan-Meier curves to compare rates of VTE recurrence based on
the presence or absence of each MetS component, as well as
a composite “1MetS” group (requiring at least 3 of the 4 components)
vs “2MetS.” Kaplan-Meier curves were compared using the log-
rank (Mantel-Cox) test. Further, we also created a multiple logistic
regression model to test the independent predictive value of age,
sex, hypertension (HTN), hyperlipidemia, DM, obesity, Afib, COPD,
CHF, CKD, anxiety, depression, stroke, MI, cancer, and smoking
history on VTE recurrence and mortality. Both unadjusted and
adjusted odds ratios (ORs) and 95% confidence intervals (CIs)
were calculated for the selected variables to assess the association
with both recurrence and mortality rates. In post hoc exercises, we
measured the prevalence and duration of anticoagulation prescrip-
tion and compared between 1MetS and 2MetS groups.
Results
Demographic data and descriptive statistics
This study included a total of 151054 patients with DVT studied from
2004 to 2017, representing 0.9 million patient-years. Table 1 displays
the demographic and clinical characteristics of these patients. The
average age across the entire DVT cohort was 58 years. Fifty-six
percent of patients were female and 69% identified as white. Of the
4 MetS components, HTN was found to be the most common
comorbid condition, present in 58% of all patients. This was followed
by hyperlipidemia (41%), DM (23%), and obesity (19%). Table 1 also
stratifies patients according to the number of MetS criteria they were
found to have (ranging from 0 to 4). Sixty-eight percent of patients
with DVT had at least 1 comorbid MetS diagnosis. Specifically, 22%
had 1 component, 24% had 2 components, 17% had 3 components,
and 5% had all 4 components. Those with fewer MetS criteria tended
to be younger, have a less frequent smoking history, and have fewer
comorbidities overall.
Table 1 also reports outcome data for the entire DVT cohort, as well
as stratified by number of comorbid MetS components, specifically
displaying percent mortality, VTE recurrence rate and average
number of return ED visits per patient over a 2-year span after DVT
diagnosis. Across all included patients, we found a 16% mortality
rate, a 17% VTE recurrence rate, and an average of 1.9 per patient
return ED visits. When stratified by number of MetS components,
VTE recurrence rate demonstrated a stepwise increasing association
with each additional MetS criteria. Patients with 0 MetS components
had a VTE recurrence rate of 7%, followed by 14%with 1 component,
21% with 2 components, 30% with 3 components, and 37% with all
4 components. A similar stepwise result was found on examina-
tion of the effect of number of MetS comorbid diagnoses on return
ED visits. This stepwise association was not demonstrated in
percent mortality, where no clear pattern was found when
stratified by number of MetS criteria. The mortality rate for each
groupwas as follows: 12%with 0 components, 20%with 1 component,
18% with 2 components, 17% with 3 components, and 13% with all 4
components.
Unadjusted ORs for recurrence and mortality
Table 2 demonstrates the unadjusted univariate ORs both for VTE
recurrence and mortality across all MetS components and addi-
tional comorbidities of interest. Three of the 4 MetS components
represented the 3 largest unadjusted ORs for VTE recurrence:
hyperlipidemia 2.9 (95%CI, 2.84-3.00), HTN 2.8 (95%CI, 2.70-2.87),
and obesity 2.7 (95% CI, 2.64-2.81). The 3 disease processes
determined to have the largest magnitude unadjusted ORs for
mortality were CHF 3.7 (95% CI, 3.54-3.75), CKD 2.8 (95% CI,
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2.72-2.89), and COPD 2.6 (95% CI, 2.53-2.68). Two of the MetS
criteria, hyperlipidemia (0.9; 95% CI, 0.87-0.92) and obesity
(0.9; 95% CI, 0.86-0.92), had significant ORs ,1, suggesting
a negative relationship between these conditions and mortality.
Multivariate analysis of recurrence data
We performed multivariate logistic regression analysis with VTE
recurrence as the dependent variable and several predefined predictor
variables, the results of which are displayed in Tables 2 and 3. All
conditions except for CHF (OR, 1.0; 95%, CI 0.96-1.03) and MI (OR,
1.0; 95% CI, 0.96-1.06) were found to be associated with significantly
greater odds of VTE recurrence. The 4 MetS criteria had the 4 largest
adjusted ORs for VTE recurrence, with an OR of 1.8 (95% CI, 1.72-
1.84) for hyperlipidemia, 1.5 (95%CI, 1.48-1.59) for obesity, 1.5 (95%
CI, 1.41-1.53) for HTN, and 1.4 (95% CI, 1.38-1.47) for DM. These
adjusted ORs for recurrence are displayed in Figure 1.
Table 1. Clinical characteristics and outcomes stratified by number of MetS criteria
0 1 2 3 4 All
Total patients 48043 33769 36360 25168 7714 151054
Average age, y 52 58 62 60 57 58
Female, % 55 57 55 56 59 56
White, % 64 67 70 74 78 69
African American, % 8 12 13 14 13 11
HTN, % 0 6 92 98 10 58
Hyperlipidemia, % 0 16 72 92 100 41
DM, % 0 12 21 59 100 23
Obesity, % 0 7 15 51 100 19
Afib, % 4 16 26 30 32 18
COPD, % 8 24 35 43 48 26
CHF, % 5 21 33 43 46 24
CKD, % 3 17 29 38 38 20
Anxiety, % 2 4 5 8 10 4
Depression, % 8 22 31 41 49 24
Stroke, % 2 9 16 20 18 11
MI, % 1 5 12 16 16 8
Cancer, % 10 15 1 16 15 14
Smoking history, % 13 24 34 42 49 27
VTE recurrence, % 6.8 13.8 20.8 30.1 37.1 17.2
Mortality, % 11.6 20.2 18.1 16.7 13.0 16.0
Average no. of return ED visits (per patient) 1.1 1.7 2.1 2.7 3.0 1.9
Table 2. ORs for VTE recurrence and mortality
Variable
OR VTE recurrence (95% CI) OR for mortality (95% CI)
Unadjusted Adjusted Unadjusted Adjusted
HTN 2.784 (2.700-2.872) 1.470 (1.413-1.529) 1.980 (1.922-2.041) 1.209 (1.163-1.258)
Hyperlipidemia 2.924 (2.844-3.006) 1.779 (1.721-1.839) 0.897 (0.872-0.922) 0.444 (0.428-0.460)
DM 2.102 (2.041-2.164) 1.419 (1.375-1.465) 1.082 (1.048-1.118) 0.901 (0.869-0.934)
Obesity 2.725 (2.645-2.808) 1.535 (1.484-1.588) 0.890 (0.858-0.922) 0.767 (0.735-0.800)
Afib 1.985 (1.924-2.048) 1.415 (1.363-1.468) 2.514 (2.437-2.594) 1.205 (1.160-1.251)
COPD 1.920 (1.866-1.975) 1.064 (1.028-1.101) 2.603 (2.530-2.679) 1.577 (1.523-1.634)
CHF 1.857 (1.804-1.912) 0.995 (0.958-1.033) 3.647 (3.543-3.753) 2.135 (2.056-2.218)
CKD 1.879 (1.823-1.937) 1.111 (1.072-1.152) 2.806 (2.723-2.891) 1.665 (1.605-1.726)
Anxiety 2.238 (2.122-2.361) 1.168 (1.102-1.239) 0.947 (0.885-1.013) 0.841 (0.781-0.906)
Depression 2.325 (2.260-2.393) 1.340 (1.297-1.385) 1.504 (1.459-1.550) 1.309 (1.262-1.357)
Stroke 2.195 (2.116-2.277) 1.408 (1.352-1.466) 2.139 (2.060-2.221) 1.315 (1.260-1.372)
MI 1.968 (1.885-2.055) 1.010 (0.963-1.060) 2.479 (2.376-2.586) 1.416 (1.348-1.486)
Cancer 1.306 (1.259-1.355) 1.255 (1.207-1.305) 2.255 (2.179-2.333) 1.993 (1.921-2.068)
Smoking history 2.071 (2.014-2.130) 1.266 (1.227-1.307) 1.106 (1.073-1.140) 0.935 (0.902-0.969)
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Survival analysis of recurrence data
Figure 2 displays the individual Kaplan-Meier curves for VTE
recurrence over time based on the presence or absence of each
MetS component. These were all significant (P , .0001), with
survival analysis yielding the following hazard ratios (HR): HR,
2.2 (95% CI, 2.12-2.23) for HTN; HR, 2.3 (95% CI, 2.24-2.36)
for hyperlipidemia; HR, 1.8 (95% CI, 1.76-1.86) for DM; and HR
2.2 (95% CI, 2.11-2.24) for obesity. Kaplan-Meier analysis was
also performed to compare rates of VTE in patients classified as
having MetS (composite1MetS group, requiring at least 3 of the 4
MetS components) vs those without MetS (2MetS group). The
curves were significantly different (P , .0001) between these 2
groups, with an HR of 2.4 (95% CI, 2.32-2.46) for VTE recurrence in
1MetS (Figure 2).
Multivariate analysis of mortality data
Similar logistic regression analysis was performed with mortality
as the dependent variable, as demonstrated in Tables 2 and 3.
The variables associated with the greatest odds of mortality were
CHF (OR, 2.1; 95% CI, 2.06-2.22), cancer (OR, 2.0; 95% CI,
1.92-2.07), and CKD (OR, 1.7; 95% CI, 1.61-1.73). The ORs for
the following variables exhibited a significant negative association
with mortality: hyperlipidemia (OR, 0.4; 95% CI, 0.43-0.46),
obesity (OR, 0.8; 95% CI, 0.74-0.80), anxiety (OR, 0.8; 95% CI,
0.78-0.91), DM (OR, 0.9; 95% CI, 0.87-0.93), and smoking
history (OR, 0.9; 95% CI, 0.90-0.97). These adjusted ORs for
mortality are displayed in Figure 1.
Analysis of anticoagulation data
In post hoc exercise, we measured the prevalence and duration
of anticoagulation prescription and compared between 1MetS
and 2MetS groups. Patients with the composite 1MetS profile
had a documented prescription for an anticoagulation medica-
tion in 23% of cases, compared with 18% of patients without MetS
(P , .0001), with the initial anticoagulation prescription occurring
5 days after index DVT in those with MetS compared with 1 day
in those without MetS (P , .0001). We also measured days
from index DVT to the most recent documented prescription for
anticoagulation as a surrogate measure of duration of therapy,
Table 3. Multivariate logistic regression analysis for VTE recurrence and mortality
Variable
VTE recurrence Mortality
Parameter estimate P Parameter estimate P
Age 20.0128 ,.0001 0.0195 ,.0001
Sex 0.0144 .3296 20.00664 .6688
HTN 0.3853 ,.0001 0.1900 ,.0001
Hyperlipidemia 0.5760 ,.0001 20.8118 ,.0001
DM 0.3501 ,.0001 20.1045 ,.0001
Obesity 0.4287 ,.0001 20.2650 ,.0001
Afib 0.3468 ,.0001 0.1862 ,.0001
COPD 0.0619 .0004 0.4558 ,.0001
CHF 20.00542 .7793 0.7586 ,.0001
CKD 0.1051 ,.0001 0.5095 ,.0001
Anxiety 0.1557 ,.0001 20.1730 ,.0001
Depression 0.2930 ,.0001 0.2690 ,.0001
Stroke 0.3421 ,.0001 0.2737 ,.0001
MI 0.0101 .6804 0.3476 ,.0001
Cancer 0.2271 ,.0001 0.6897 ,.0001
Smoking history 0.2360 ,.0001 20.0674 .0003
CHF
0.5 1
Adjusted odds ratios for VTE recurrence
2
MI
COPD
CKD
Anxiety
Cancer
Smoking history
Depression
Stroke
Afib
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HTN
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A
Hyperlipidemia
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Adjusted odds ratios for mortality
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B
Figure 1. Results from multivariate logistic regression analyses. Adjusted
odds ratios for VTE recurrence (A) and mortality (B).
130 STEWART and KLINE 14 JANUARY 2020 x VOLUME 4, NUMBER 1
finding a longer duration in those with MetS (92 days vs 50 days,
P , .0001).
Discussion
To our knowledge, this is the largest cohort of DVT patients that
has found that MetS plays an important role in VTE recurrence.
The descriptive data show a clear positive concordance between
the number of MetS criteria and recurrence rate. Percent
recurrence increased in a stepwise fashion with each additional
MetS component, ranging from 7% recurrence in patients
without any MetS comorbidities to 37% recurrence in those with
all 4 components. In multivariate analyses, the MetS components
represented the 4 most important risk factors for VTE recurrence
across all diseases, generating the 4 largest adjusted ORs. This
was highest for hyperlipidemia, followed by obesity, HTN, and
DM. Results of the Kaplan-Meier curve analysis suggest that both
the composite 1MetS diagnosis as well as the presence of each
individual MetS component are important contributors to this
recurrence risk. Further, in our analysis of anticoagulation data,
this association of MetS with higher risk of VTE recurrence persisted
despite those with MetS having higher documented rates and
duration of anticoagulation therapy. Thus, as anticoagulation therapy
is known to be very effective at reducing the risk of recurrent VTE,
it is possible that the effect of MetS on recurrence is actually
underestimated in our dataset. Taken together, these data
strongly support the hypothesis that MetS increases risk of VTE
recurrence after DVT. Prior studies have suggested an increased
risk of VTE in patients with MetS, although results have varied
and remain inconclusive.15-24 The underlying pathophysiology
explaining the role of MetS in VTE is unclear. One proposed
mechanism involves obesity-induced adipocyte dysregulation and
oxidative stress, resulting in increased circulating proinflamma-
tory adipocytokines including interleukin-6, tumor necrosis factor-
a, and PAI-1. This creates a low-grade proinflammatory and
prothrombotic state, which may contribute to a higher risk of
recurrent VTE.11-14
Somewhat contrary to the observation that MetS increased VTE
recurrence, patients with 3 of the 4 MetS components (hyperlip-
idemia, DM, and obesity) survived longer than patients without
these conditions. The potential explanation of longer survival
allowing for a longer period of surveillance and therefore greater
chance of recurrent VTE seems unlikely. The hazard curves in
Figure 2 show a clear separation in VTE recurrence based upon
MetS status starting at about 800 days, before the time of
separation of survival curves (data not shown). Further, these
curves correct for loss of patients because they censor patients
after death. Our data do not allow a clear explanation for the
lower mortality rate for DVT patients with hyperlipidemia, DM,
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Figure 2. Kaplan-Meier curves for VTE recurrence
based on 6 composite MetS and individual
components.
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and obesity, but we are not the first to observe a survival benefit
of obesity in cardiovascular disease. Indeed, this phenomenon
has been described frequently enough in other cardiovascular
diseases to receive the descriptive label of the “obesity
paradox.”25-28 Additionally, similar to this obesity paradox, results
from multiple studies have shown high cholesterol levels to be
associated with improved outcomes and long-term survival after
acute ischemic stroke, independent of statin therapy.29-31 As with
obesity, the protective mechanism of elevated cholesterol remains
speculative.32,33
We believe this study to be novel in its size and scope because it
includes .150000 patients with DVT, allowing for small CIs. We
found the components of MetS to be prevalent in patients
diagnosed with DVT, with 68% of patients having at least 1 of
these comorbid conditions. Because these diagnoses were reliant
on ICD coding, it is very possible that they make up even larger
proportions of the population than reported here. Further
research is needed to better elucidate the role of MetS in
VTE, particularly in its effect on morbidity-related outcomes
such as recurrence and health care utilization because this
could aid in decision-making regarding implementation of the
most appropriate adjuvant therapies in those diagnosed with
DVT. We believe this to be an area of significant importance
in the treatment of DVT because the components of MetS
represent common, often undertreated, and potentially modifi-
able risk factors in these patients. Potential adjuvant interven-
tions in patients with the components of MetS diagnosed with
DVT might include systems-based efforts aimed toward the
implementation of exercise programs, dietary education, or
targeted nonfibrinolytic pharmacologic agents. Exercise has
been previously shown to carry with it an antithrombotic effect
through the reduction of plasma fibrinogen and increased
endogenous tPA activity, weight loss, and improved exercise
capacity in patients with VTE.34-37 Several nonfibrinolytic
agents, including statins and nonsteroidal anti-inflammatory
medications, have been proposed as a method of attenuating
the acute inflammatory response after PE.38-40
The additional non-MetS comorbidities chosen for inclusion in
this analysis represented common disease processes that may be
frequently encountered in patients with a new diagnosis of DVT.
Included in these selected comorbidities were several accepted
risk factors of VTE including cancer, CKD, and age. Because of
the design of this study and limitations based on reliance on ICD
coding, we were unable to include all traditional major risk factors
for VTE such as immobility, trauma, or recent surgery. We also
selected comorbidities without a previously established associ-
ation with VTE, including atrial fibrillation, COPD, CHF, anxiety,
depression, stroke, and MI. Multivariate analysis yielded sev-
eral associations between these predictor variables and VTE,
which we found to be somewhat surprising and of unclear
significance. Specifically, we found Afib, stroke, depression, and
anxiety to have significant adjusted ORs for recurrence, even
higher than that of CKD and cancer, for all but anxiety. Although
this work provides no biological mechanism to understand these
observed associations, prior studies have demonstrated anxi-
ety and depression to be associated with a pro-inflammatory
phenotype.41,42 A large, prospective population-based study
has previously reported an apparent association between
both Afib and ischemic stroke with VTE risk.43-45 However, the
potential link between these risk factors and VTE requires further
investigation.
There are several limitations of this study. The overall size and reach
of this study resulted in challenges with data collection. First, the
identification of the presence or absence of the MetS components
was dependent on ICD coding. It is likely that these diagnoses are
undercoded and actually represent a larger proportion of patients
included in the dataset. Specifically, we noted discrepancies between
patient weight data and the diagnosis of obesity, suggesting that this
may be a diagnosis that is not consistently formally coded for across
health care providers. A 19%overall prevalence of obesity is lower than
what we would expect based on the study population. Because of
these limitations, we defined MetS based on a surrogate collection of
ICD codes for hypertension, hyperlipidemia, diabetes, and obesity. This
differs from many of the more specific guidelines traditionally used to
define MetS, including specific cutoffs for triglycerides, high-density
lipoprotein, systolic and diastolic blood pressure, fasting glucose, and
waist circumference.10 It is possible that the prevalence of patients
diagnosed with MetS may have differed if we had been able to follow
these more stringent guidelines. Given this limitation, it may be more
precise to consider this a study aimed at the evaluation of the
association of VTE with traditional cardiovascular risk factors,
taken both individually and as a cluster. The lack of discrete data
points, including specific blood pressure readings, fasting lipid
panels for those with hyperlipidemia and hemoglobin A1c for
those with DM, limits interpretation of results. Additionally,
diagnosis of index DVT was also based on ICD coding. We did
not have access to specific ultrasound results to verify these
diagnoses. Therefore, diagnoses of DVT likely differ based on
location and overall size of thrombus burden and may include
more superficial thromboses if coded as such by individual
providers. Prior database studies have reported only a modest
predictive value of ICD codes in the identification of VTE, citing
a positive predictive value of 49%, with this being even more
challenging when attempting to identify recurrent VTE.46 It is
possible that a portion of the coded “recurrent” events in our
dataset actually represents the previously diagnosed DVT instead
of a true recurrence.
Another limitation involves our ability to determine the particu-
lar treatment (or lack thereof) that patients received after DVT
diagnosis and how this affected outcomes. Although oral
anticoagulation therapy is very effective at reducing the risk of
recurrent VTE while on therapy, this protection is not maintained
after treatment cessation.5 We attempted to account for the
role of anticoagulation therapy by comparing prevalence and
duration of anticoagulation prescription in patients with and
without MetS. That our database was able to identify only 18%
and 23% of patients without and with MetS, respectively, who
received outpatient prescriptions for anticoagulation suggests
inadequate access of the Indiana Health Information Exchange
database to prescription data. However, we have no reason to
believe that the scope of reach for the data repository differed
for patients based upon MetS status. Additional adjuvant
pharmacologic therapies such as statins and aspirin may also
reduce one’s risk of recurrent VTE.40,47-50 Finally, it should be
noted that, given the extended duration of this study, our results
may have been influenced by changes in clinical practice over
time. For instance, the American College of Chest Physicians
started to recommend the use of indefinite anticoagulation in
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patients with unprovoked VTE in 2008.51 In this same year,
multiple studies reported obesity to be a risk factor for VTE
recurrence and recommended appropriate risk stratification in
this group.52,53 In a subgroup comparison of patients with DVT
diagnosed before vs after 2008, we found those with obesity
to have a higher likelihood of anticoagulation prescription if
diagnosed after 2008. However, these patients remained at
higher risk of recurrence despite more frequent anticoagulation
therapy.
In conclusion, in a large cohort with long-term follow-up, we found
the presence of any 1 component of MetS in patients with DVT to
independently increase the risk of VTE recurrence; this risk of VTE
recurrence increased successively with each additional component
of MetS. These findings support the importance of recognizing
MetS components in patients diagnosed with acute DVT and
initiating appropriate therapies to reduce their effect on VTE
recurrence risk.
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